Africa's Medical Device Regulation Is Speeding Up — and October 2026 Is the Proof

For years, medical device manufacturers planned African market entry as an afterthought: ship after Europe or the US, handle the paperwork locally, rely on the distributor. That sequence no longer works — and October 2026 is the month that proved it.

Four regulatory signals landed within days of each other. Together, they describe a market-access environment becoming more structured, more demanding — and, for prepared manufacturers, more predictable. This article summarizes official documents and contemporaneous reporting. Requirements change; confirm every detail with the relevant authority and qualified local advisors before committing a calendar or a budget. Professional review is required before business use.

1. The regulators just met — and were told to turn talk into action

The sixth PharmaReg and MedDevReg AfriSummit closed in Nairobi on October 2, bringing together 16+ national regulatory authorities and notified bodies, 100+ speakers, and 450+ decision-makers from more than 25 countries — the first time the summit was hosted in East Africa.

The closing message was blunt. Dr. John M. Munyu, chairperson of Kenya's Pharmacy and Poisons Board, told delegates the summit's success would be measured “not by the number of presentations delivered or discussions held, but by what we do with the knowledge we have gained.”

Kenya's Cabinet Secretary for Health, Aden Duale, challenged stakeholders to deepen harmonization, embrace regulatory reliance, and support local manufacturing. Reliance — national authorities drawing on assessments from trusted reference bodies — was framed as the mechanism to reduce duplication and accelerate access.

The read: the continent's top regulators are no longer debating whether to harmonize. The conversation has moved to how fast.

2. A new ten-year strategy is now the reference frame

At the 76th WHO Regional Committee for Africa in Addis Ababa (August 2026), health ministers endorsed the Regional Strategy on Regulation of Medical Products in the African Region, 2026–2035. It is the first continent-wide regulatory strategy that treats medical devices, diagnostics, medicines, and vaccines under one coordinated frame.

The strategy's headline targets for 2035:

• 15 national regulatory authorities at WHO maturity level 3 (ML3), up from 8 in 2025 — and just 1 in 2018
• At least 40 Member States with autonomous or semi-autonomous regulatory authorities
• The African Medicines Agency (AMA) progressing toward WHO-Listed Authority status
• Electronic regulatory systems in 20+ authorities

Why this matters for device makers: ML3 trajectories determine which authorities can run reliance-based reviews and issue decisions other markets recognize. The countries moving fastest on this ladder are where dossier sequencing and local representation decisions pay off first. On the AMA specifically: its founding documents place medical devices within scope — the AU Model Law covers non-IVD medical devices, and the AMA business plan provides for regulatory guidance on medical devices and diagnostics where national capacity is limited. AMA Director-General Mimi Darko has said the agency will focus on complex products including biomedical devices. One caveat that matters for planning: AMA's role is advisory and consultative — national authorities keep their decision-making power.

3. Botswana's mandatory registration roadmap just crossed a milestone

Botswana's medicines authority BoMRA published its medical devices regulatory strategy (2022–2030), moving the country from a basic oversight model toward comprehensive lifecycle regulation under the Medicines and Related Substances Act 2025. The mandatory registration roadmap runs by risk class:

BoMRA's framework states that once a deadline passes, devices are removed from the Listing Register and must sit in the Registration Register. In parallel, BoMRA is clearing its assessment backlog: variation applications received in 2022 by August 2026, those from 2023 by October 2026 — this month — and the remainder by January 2027. The authority is also expanding reliance and recognition pathways and moving assessments onto its BRIMS electronic system.

The takeaway is not that Botswana is difficult. It is that Botswana is now legible: a published timeline, published review targets, and a defined transition from listing to registration.

4. The manufacturing conversation is about to get commercial

On October 26–28, Addis Ababa hosts AHMTEC 2026 — the third African Healthcare Manufacturing Trade Exhibition and Conference — under the theme “Industrialise to Commercialise.” The focus has shifted from building manufacturing capacity to producing competitively for regional and global markets, with regulatory harmonisation, the AMA, and pooled procurement on the agenda.

For market access, the signal is clear: regulators, manufacturers, and procurement bodies will be in one room discussing the same harmonized standards. Product strategy and regulatory strategy are converging.

What this means for a manufacturer's entry plan

Sequence feasibility before registration. The regulators' message — hospitals test, authorities register, distributors last — matches the order that works on the ground. Entering a market with a device that already has clinical validation from a respected local institution changes the registration conversation.

Plan reliance, not repetition. Where your product already holds EU, US, or other trusted-market approvals, reliance and abridged pathways are formalizing — but they require documented evidence, not assumptions. Check each authority's reference-authority list before building the dossier.

Calendar the milestones. Botswana's Class B window closes March 31, 2027. Ethiopia's EFDA met WHO on September 16 to advance its push toward WHO Maturity Level 3 for medical devices, backed by an Institutional Development Plan. Kenya, Egypt, and Ethiopia are moving to fully digital submissions with mandatory local representatives. Missing one of these is a twelve-month delay, not a paperwork fix.

Africa's device market is not becoming easier to enter. It is becoming possible to plan — and that is better news than it sounds, provided you plan early.

Sources

• Health Business Kenya — “Africa's drug regulators face push to turn summit pledges into action” (6 Oct 2026): https://healthbusiness.co.ke/10830/africas-drug-regulators-face-push-to-turn-summit-pledges-into-action/
• WHO Regional Office for Africa — “African health ministers adopt new strategy to bolster medical regulatory systems” (26 Aug 2026): https://www.afro.who.int/news/african-health-ministers-adopt-new-strategy-bolster-medical-regulatory-systems
• WHO AFRO — Regional strategy on regulation of medical products in the African Region, 2026–2035 (AFR/RC76/7, PDF): https://www.afro.who.int/sites/default/files/2026-07/AFR-RC76-7%20Regional%20strategy%20on%20regulation%20of%20medical%20products%20in%20the%20African%20Region.pdf
• BoMRA — Medical Devices Regulatory Strategy (PDF, Jun 2026): https://www.bomra.co.bw/wp-content/uploads/2026/06/Medical-Devices-Strategy.pdf
• WHO AFRO press release — WHO and EFDA strengthen collaboration on medicines and medical devices regulation (16 Sep 2026): https://who-africa.africa-newsroom.com/press/world-health-organization-who-and-ethiopian-food-and-drug-authority-efda-strengthen-collaboration-on-medicines-and-medical-devices-regulation
• Daily Economy — “African health manufacturers meet in Addis Ababa for AHMTEC 2026”: https://dailyeconomy.ng/african-health-manufacturers-meet-in-addis-ababa-for-ahmtec-2026-as-focus-shifts-from-building-capacity-to-commercial-scale/
• AfriSummit 2026 (Nairobi, 28 Sep–2 Oct 2026): https://sokodirectory.com/2026/09/afrisummit-2026-to-bring-africas-regulatory-and-healthcare-community-together-in-nairobi/